Phase III Data Show Significant Benefit of Novartis Drug Afinitor in Patients With Non-Cancerous Tumors Associated With TSC

Data published in The Lancet shows patients on Afinitor (everolimus) tablets with non-cancerous kidney tumors associated with tuberous sclerosis complex (TSC) experienced a significant reduction in tumor size and the absence of tumor progression.
PR Newswire